DOXORUBICINE TEVA 200 mg/100 ml, solution for injection bottle, 100 ml
Active ingredients: Doxorubicin hydrochloride
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injectionbottle, 100 mlintraveineuse
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- DOXORUBICINE TEVA 200 mg/100 mL, solution injectable
- Pharmaceutical form
- solution injectable
- Route of administration
- intraveineuse
- Presentation description
- 1 flacon(s) en verre de 100 ml
- Marketing authorisation holder
- TEVA SANTE
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 19 Feb 2025
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
69467732CIP75594895CIP133400955948957Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CHLORHYDRATE DE DOXORUBICINEsolution | 200 mg · un flacon | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The published catalog does not list other packages of similar medicines.